Please read this leaflet carefully as it provides a summary of the information available on your babys medicine. This video shows administration of surfactant in nicu by dr ajay agadesurfactant is a novel and revolutionary therapy in management of respiratory distress syndrome in neonates. View label archives, rxnorm, get label rss feed, view ndc codesnew. Creation and evaluation of a twothreedimensional molecular. Refer to specific instruction provided by manufacturer for proper dosing technique. Curosurf 120mg vial endotracheopulmonary instillation. These highlights do not include all the information needed to use. Beractant, calfactant, and poractant alpha are available in the united states.
Curosurf is an extract of natural porcine lung surfactant consisting of 99% polar lipids mainly phospholipids and 1% hydrophobic low molecular weight proteins. Tell all of your childs health care providers that your child is taking poractant alfa curosurf. Comparing the efficacy of two natural surfactants, curosurf and alveofact, in treatment of respiratory distress syndrome in preterm infants. Pharmaceutical composition according to any one of claims 35 to 38, wherein the pulmonary surfactant is selected from the group consisting of poractant alfa, beractant, bovactant1 colfosceril palmitate1 surfactantta, calfactant, pumactant, lusupultide or sinapultide. A total of 332 preterm infants at 2431 weeks gestation with respiratory distress syndrome rds were enrolled and allocated to three groups according to the surfactant instilled.
The nlm drug information portal gives users a gateway to selected drug information from the national library of medicine and other key government agencies. Lexicomp, mims online, amh childrens dosing companion. Poractant alfa versus beractant for respiratory distress. Speer et al compared curosurf to survanta in a pilot study, with a number of shortterm endpoints defined for oxygenation or ventilator settings. This information from lexicomp explains what you need to know about this medication, including what its used for, how to take it, its side effects, and when to call your healthcare provider. Study design randomized, partiallyblinded, multicenter trial. Sales of curosurfr poractant alfa, a pulmonary surfactant, exceeded euro200m, growing by 14. Infants poractant alfa or bovine lipid extract surfactant. To compare the pharmacy costs of calfactant infasurf, ony, inc. Due to lack of structural information, the following identified drugs were not constructed in two and three dimensions, the monoclonal antibody omalizumab, c1esterase inhibitor, dornase alfa, and the pulmonary surfactants beractant and poractant alfa. Uses for poractant alfa respiratory distress syndrome rds treatment rescue of rds hyaline membrane disease in premature neonates designated an orphan drug by fda for this use. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. B115, alpha m8, alpha em, s2 subbass, alpha ef, b118. Efficacy of surfactantta, calfactant and poractant alfa for preterm infants with respiratory distress syndrome.
Poractant alfa is a pulmonary surfactant sold under the brand name curosurf by chiesi farmaceutici. Unlike other intelligence solutions, bciq exclusively supports the unique needs of the biopharma industry and. Find, read and cite all the research you need on researchgate. Its ability to modify lipid properties and restore lung compliance was investigated with circular dichroism, differential scanning calorimetry, and solidstate nmr spectroscopy.
For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, bciq provides accurate information and context to support profitable and strategic decision making. Respiratory distress syndrome rds is the leading cause of respiratory insufficiency, as well as mortality and morbidity in preterm infants. This web page contains comprehensive information about ndc code 1012251003. For these reasons, the reader is strongly advised to consult the drug companies printed information before administering any of the drugs recommended in this book. How much these differences affect the acute pulmonary response to treatment is. Poractant alfa and beractant are the commonly used. They differ in their source, composition, pharmaceutical form, and clinical dose. Data from 200 infants who met the inclusion criteria were analyzed.
Capitals indicate lifethreatening, underlines indicate most frequent. Natural derived surfactant preparation as a carrier of. Although the initial dose of curosurf was twice that of survanta 200mgkg versus. As with other surfactants, marked improvement on oxygenation may occur within minutes of the administration of poractant alfa. I spent november 1984 in stockholm comparing our synthetic surfactant turfsurf with curosurf, both in vitro and in bengts 27. A pharmacoeconomic analysis of inhospital costs resulting. To avoid potential sequelae of endotracheal et intubation and mechanical ventilation, prophylactic aerosolization of surfactant delivered via ncpap has been attempted with limited success. Listing a study does not mean it has been evaluated by the u. There are no data on the use of poractant alfa curosurf during lactation. Pdf an open label comparison of calfactant and poractant. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress.
The avoiding mechanical ventilation amv trial was a multicentre, randomised, controlled parallelgroup study done at 12 neonatal intensive care units level three in germany between october, 2007, and january, 2010. Multicentre, double blind, randomized, non inferiority, active. Curosurf poractant alfa dose, indications, adverse. This includes your childs doctors, nurses, pharmacists, and dentists. Therefore, infants receiving curosurf should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to respond to respiratory changes. Poractant alfa is an extract of natural porcine lung surfactant consisting of 99% polar lipids mainly phospholipids and 1% hydrophobic low molecular weight proteins surfactant associated proteins spb and spc. View and download nexo alpha m3 user manual online. Nebulized surfactant, poractant alfa, eflowneos, respiratory distress syndrome, cpap, neonatal ventilation. Group 1 n146, surfactantta, group 2 n96, calfactant, and group 3 n90, poractant alfa. Kl4 binds fluid lamellar phase pcpg lipid membranes and forms an amphipathic. Contains porcine pancreatin formulated as entericcoated acidresistant minimicrospheres within gelatin capsules. There were no differences between studies or treatment groups in the overall extubation rate.
Poractant alfa drug monograph pediatric care online. Poractant alfa is an extract of natural porcine lung surfactant. South australian neonatal medication guidelines poractant alfa 80mgml 1. The results showed that ros levels, the expression of senp1, rate of sirt1 nucleocytoplasmic shuttling, and apoptotic cells were reduced. The term hyaline membrane disease is now less commonly used in clinical practice to describe the constellation of pathologic, clinical, and radiologic findings produced by pulmonary surfactant insufficiency in infants. Between 2005 and 2007, poractant alfa and beractant were alternated every month in our neonatal intensive care unit for 27 months.
Refer to medication resources for dosing information. The recommendations in this online publication do not indicate an exclusive course of treatment or serve as a standard of medical care. Curosurf and survanta treatmentcastof rds in very premature. The primary outcome was being alive and extubated at 48 hours post. Effect of two different early rescue surfactant treatments on. Poractant alfa should only be administered to pregnant women where the potential benefit of the medication would outweigh the unknown risks to the fetus. Treatment with poractant alfa 200 mgkg initial dose resulted in rapid.
Poractant alfa is an exogenous pulmonary surfactant extracted from porcine lungs. It is a natural porcine lung extract consisting of 99% polar lipids mainly phospholipids and approximately 1% hydrophobic low molecular weight proteins surfactant associated proteins spb and spc. Here, the optimal dose and its performance in comparison to the animalderived surfactant poractant alfa were investigated. Curosurf poractant alfa is intended for intratracheal use only. Curosurf aka poractant alfa is a human prescription drug product labeled by chiesi usa, inc.
Curosurf and survanta treatmentcast of rds in very premature infants cast. Up to 4 doses of beractant are administered during the first 48 hours, no more frequently than every 6 hours. It decreases surface tension of the lungs, thereby improving lung expansion and gaseous exchange. Pulmonary surfactant protein b spb is an essential protein for lowering surface tension in the alveoli. Chf5633 is a new generation synthetic surfactant containing both spb and spc analogues developed for the treatment of respiratory distress syndrome.
Surfactant administration in the nicu royal childrens. Jun 28, 2018 curosurf is administered via the endotracheopulmonary route in infants whose heart rate and arterial oxygen concentration or oxygen saturation are being continuously monitored as it is usually feasible in neonatal units. Open in figure viewer powerpoint bengt robertson ro and tore curstedt cu at lake geneva the creators of the porcine surfactant curosurf, also known as poractant alfa. Table 3 shows details of trial design for each of these. In view of the relevant role played by inflammation in the development of. Your child will be closely watched while taking poractant alfa curosurf. Medscape rescue treatment for respiratory distress syndrome dosing for curosurf poractant alfa, frequencybased adverse effects, comprehensive. A cost minimization comparison of two surfactantsberactant and poractant alfabased upon prospectively designed, comparative clinical trial data article pdf available april 2004 with 547 reads. Poractant alfa is a sterile, nonpyrogenic pulmonary surfactant intended for intratracheal use only.
Curosurf is administered via the endotracheopulmonary route in infants whose heart rate and arterial oxygen concentration or oxygen saturation are being continuously monitored as it is usually feasible in neonatal units. Dropping into the mixture of budesonide and poractant alfa was better than just poractant alfa only. Poractant alfa and beractant treatment of very premature infants with. Oct 06, 2008 curosurf and survanta treatmentcast of rds in very premature infants cast the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. In vitro and in vivo characterization of poractant alfa. Nevertheless, their clinical information was included in the database. The rch nicu butterfly ward uses poractant alfa curosurf which is a natural porcine surfactant.
Chiptuning tools tuning file service for professionals register upload file chiptuning tools a chiptuning tool is used for reading and writing the engine management software. Nasal continuous positive airway pressure ncpap is an accepted mode of respiratory support for preterm infants with respiratory insufficiency. No difference was found between the two methods in terms of dosingrelated hypoxemia. Pdf a cost minimization comparison of two surfactants. Infasurf, poractant curosurf and bovactant alveofact. Follow instructions carefully regarding installation of drug and ventilation of infant. Circular dichroism has shown that when spb125 interacts with negatively charged lipid vesicles, it contains significant helical structure for the. Curosurf poractant alfa dose, indications, adverse effects. Therefore, infants receiving curosurf should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to. Poractant alfa is an extract of natural porcine lung surfactant consisting of 99% polar lipids mainly phospholipids and 1% hydrophobic low molecular weight proteins surfactant associated proteins spb. Efficacy of surfactantta, calfactant and poractant alfa for preterm.
Efficacy of surfactantta, calfactant and poractant alfa. A cost minimization comparison of two surfactantsberactant. Since data are not available, poractant alfa should be administered with caution during breastfeeding. What are some things i need to know or do while i take poractant alfa. Fill the catheter with poractant alfa and discard excess through the catheter so that only the total dose to be given remains in the syringe. Frontiers in vivo evaluation of the acute pulmonary. Curosurf poractant alfa for the treatment of infants at risk for or. Pdf we compared the onset of clinical response and safety of two surfactants. Average mv duration following reintubation was similar between groups in both trials.
Morbidities and mortality rates were compared between infants who received initial doses of 200 mgkg poractant alfa and 100 mgkg beractant. Each ml of suspension contains 80 mg poractant alfa surfactant extract that includes 76 mg of phospholipids and 1 mg of protein of which 0. Elsewhere, the first dose was given after admission to the neonatal unit, although clinicians were encouraged to administer it as soon as possible after birth and within 30 min of intubation. The administration of exogenous surfactants, including curosurf, can rapidly affect oxygenation and lung compliance. With pdfpenpro, you can add text, images, and signatures to your pdfs and so much more. A randomized trial comparing beractant and poractant. Information on the cost of poractant alfa in the us was identified, however no costeffectiveness evaluations were identified. Kl4 is a 21residue functional peptide mimic of lung surfactant protein b, an essential protein for lowering surface tension in the alveoli. Decreasing equity allocation and substituting a portable alpha strategy 2.
Poractant alfa definition of poractant alfa by medical. Poractant alfa 100 mgkg 125 mlkg or pumactant 100 mg 12 ml were administered according to the manufacturers guidelines. Beractant is provided as a suspension containing 25 mg phospholipidml in 0. Mar 29, 2019 our aim was to study how the animalderived surfactant poractant alfa curosurf affects the activities of polymyxin e and gentamicin against pseudomonas aeruginosa. The hour interval following the second surfactant dose was selected for study, when the subjects were otherwise clinically. Pdf comparing the efficacy of two natural surfactants. Most of the early trials of poractant alfa were in europe where it has been approved for marketing for more than 10. Nov 17, 2019 what are some things i need to know or do while i take poractant alfa. Curosurf poractant alfa dosing, indications, interactions, adverse. We studied 52 infants 24 07 to 29 67 weeks gestation. In general, hyaline membranes are not specific histologic evidence of surfactant deficiency, but they may form in the aftermath. Poractant alfa and beractant are the commonly used animal derived surfactants in preterm infants with respiratory distress syndrome. Dongle installation for windows plug the dongle the pc will install the usb driver select run autorun. Poractant alfa were dripped into inner tracheal in 6 h after birth.
Spb125, a peptide comprised of the nterminal 25 aminoacid residues of spb, is known to retain much of the biological activity of spb. Each ml of suspension contains 80 mg poractant alfa surfactant extract. Your child will be closely watched while taking poractant alfa. It is an extract of natural porcine lung surfactant consisting of 99% polar lipids mainly phospholipids and 1 % hydrophobic low molecular. In vitro antimicrobial assays and a neonatal nearterm rabbit model were used to evaluate the combinations of antibiotics and surfactant against pseudomonas aeruginosa. The effects of nebulized poractant alfa on arterial gas exchange and lung. An open label, pilot study of aerosurf combined with ncpap. Pdf comparison of the pharmacoeconomics of calfactant. Variations, taking into account individual circumstances, may.
Determining the source for funding a portable alpha allocation is a critical decision since it has direct impacts on risk budgeting, asset allocation, and performance measurement. There were 112 patients in the poractant alfa group and 88 patients in beractant group. Lipid polymorphism induced by surfactant peptide spb125. Penetration depth of surfactant peptide kl4 into membranes is. Curosurf poractant alfa is a sterile, nonpyrogenic pulmonary surfactant intended for intratracheal use only. Budesonide and poractant alfa prevent bronchopulmonary.
420 1329 832 178 705 71 261 1367 37 1301 1239 1298 937 527 649 715 1527 1559 708 981 285 661 47 1251 261 1145 1514 229 111 284 1191 464 365 1406 272 385 471 764 1038 1337 1336 1346 401 844 993 513 821